Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
Load more
@edgarvlermamd.medsky.networkOct 4, 2026, 5:58 PM

Select RCTs, informing current management strategies for patients with SA-AKI
#Nephpearls #AKIinICU #NephJC #NephSky

👉 shop.lww.com/Handbook-of-...

@edgarvlermamd.medsky.networkOct 4, 2026, 4:52 PM

Sepsis is a syndrome defined by organ dysfunction because of a dysregulated host response to infection
#Nephpearls #AKIinICU #NephSky

📌 Septic shock is a subset of sepsis defined by hypotension requiring vasopressors to maintain an MAP >/= 65 mm Hg and serum lactate >2 mmol/L after resuscitation

@hswapnil.medsky.socialOct 4, 2026, 12:22 AM

That’s I am waiting for H4RT to be published to be convinced one way or the other for HDF

#NephSky

@nephroseeker.medsky.socialOct 3, 2026, 9:21 PM

8/ Future trials must fix the usual pitfalls:
🚩 Phenotype enrichment (LVH, high K gradient, volume overload)
🚩 Blinded adjudication
🚩Explicit competing-risk modeling
🚩Patient burden metrics
#Nephsky

@nephroseeker.medsky.socialOct 3, 2026, 9:21 PM

Dialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years.

🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough #Nephsky

academic.oup.com/ndt/advance-...

@coenneli.bsky.socialOct 3, 2026, 5:08 PM

Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial

I supported some stats, so thank you to everybody involved for this study, now in @ckj-era.bsky.social!

#Science
#WomenInSTEM
#NephSky

👉 doi.org/10.1093/ckj/...

ABSTRACT Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a cornerstone of chronic kidney disease (CKD) therapy, reducing disease progression, cardiovascular events, and mortality. Autosomal dominant polycystic kidney disease (ADPKD) patients were excluded from major trials, and data on electrolyte handling with SGLT2 inhibitors, in combination with tolvaptan, are lacking. Methods SIDIA was a randomized, double-blind, placebo-controlled, two-period crossover trial in 15 adults with ADPKD (mean eGFR 68 mL/min/1.73 m²; median age 43 years). Participants received empagliflozin 10 mg or placebo for 14 days, separated by a two-week washout. The primary endpoint was 24-hour urinary and fractional excretion of phosphate, calcium, and magnesium. Exploratory secondary endpoints included markers of kidney stone propensity, inflammation, vitamin D metabolism, and tolerability. Treatment effects were estimated using generalized linear mixed models. Given the small sample size, analyses were exploratory and focused on effect estimation. Results For the primary endpoint, neither 24-hour urinary nor fractional excretion of phosphate, calcium, or magnesium differed between empagliflozin and placebo. Empagliflozin lowered serum uric acid (–26%), increased serum magnesium (+5.7%) and urinary citrate (+78.6%), and reduced blood pressure (–4/–7 mmHg). An expected decline in eGFR (–7.1%) was observed, with no major short-term safety signals observed. Copeptin levels increased with empagliflozin (+26%). Conclusions In this exploratory mechanistic trial, no substantial short-term difference in urinary or fractional excretion of divalent ions were detected with empagliflozin. The observed changes in serum magnesium, urinary citrate, uric acid, and copeptin are hypothesis-generating and require confirmation in larger, longer-term studies.
@nephspace.bsky.socialOct 3, 2026, 3:53 PM

Want to keep up with nephrology, but end up doomscrolling instead? 🎧

NephSpace makes the nutritious stuff as easy as the scroll: the week's kidney research and news in one place, as lively episodes for the couch, the run or the commute.

2-minute trailer: nephspace.com

#NephSky #MedSky #RenalSky

@baladocritique.bsky.socialOct 3, 2026, 2:33 PM

"Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation."
Publié ce jour dans @bmj.com.
#MedSky #NephSky
www.bmj.com/content/394/...

@edgarvlermamd.medsky.networkOct 3, 2026, 12:38 AM

Treatment with maximally tolerated RAASi alone does not sufficiently slow the rate of eGFR decline in high-risk patients with IgA nephropathy #IgAN, leaving patients at risk of ESKD ca. 2026 from @asnpublications.bsky.social
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/42584957/

@drnikhilshah.bsky.socialOct 2, 2026, 10:14 PM

🎧 This Week in Nephrology — the week's key papers in a free ~10-min AI briefing.
🔬 Editor's Pick from Clinical Journal of the American Society of Nephrology

Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology?w=2026-W40

#NephSky #FOAMed

@kidneyint.bsky.socialOct 2, 2026, 5:00 PM

Meeting Report
Outcomes from the International Society of Nephrology forum on complement therapeutics in C3 glomerulopathy and IgA nephropathy

doi.org/10.1016/j.kint.2026.08.007

#NephSky #MedSky #OpenAccess #C3G #C3Glomerulopathy #IgAN #IgANephropathy #ComplementSystem #GlomerularDisease

@kidneyint.bsky.socialOct 2, 2026, 4:50 PM

Improving the histologic classification of advanced diabetic nephropathy based on the Transformative Research in Diabetic Nephropathy (TRIDENT) findings

doi.org/10.1016/j.kint.2026.07.028

#NephSky #MedSky #OpenAccess @pennmedicine.bsky.social @cedarssinaihsu.bsky.social @ksusztak.bsky.social

@kidneyint.bsky.socialOct 2, 2026, 4:28 PM

From podocyte biology to #glomerular medicine: the 15th International #Podocyte Conference 2025

doi.org/10.1016/j.kint.2026.07.026

#NephSky #MedSky @isgd.bsky.social #Podocyte2025 #ISGD #GlomerularDisease #KidneyResearch #RenalPath #TranslationalNephrology #OpenAccess

@kidneyint.bsky.socialOct 1, 2026, 9:51 PM

Nephrology Image
A pure 1-methyluric acid stone from heavy #coffee intake

doi.org/10.1016/j.kint.2026.09.012

Excessive #CoffeeConsumption can lead to 1-methyluric acid #KidneyStones, causing renal colic and impaired kidney function.

#NephSky #MedSky @unil.bsky.social @hug-ge.bsky.social

@juancarlosqvelez.bsky.socialOct 1, 2026, 2:17 AM

Interesting report. But all 4 donors had overt proteinuria at the time of organ allocation. Is it standard procedure to ignore that in deceased kidney donation? Tapping a transplantologist @georginairish.bsky.social @nymurakami.bsky.social #NephSky

@edgarvlermamd.medsky.networkSep 30, 2026, 11:03 PM

Clinical conditions related to LVADs that may arise during hemodialysis
#Nephpearls #NephSky

👉 link.springer.com/book/10.1007...

@edgarvlermamd.medsky.networkSep 30, 2026, 10:44 PM

Call 📢 for papers: "The Jerry Yee: Clinical Challenges in Diagnosis and Treatment in Nephrology"
#Nephpearls #NephSky

🗓️ Deadline for submissions: 15 October 2026

👉 www.sciencedirect.com/special-issu...

@uwnephrology.bsky.socialSep 30, 2026, 6:02 PM

Dr. Ben Lidgard discusses "Lipid Lowering in CKD: The Nephrologist's Role" in his Grand Rounds presentation @uwnephrology.bsky.social @uwdeptmedicine.bsky.social
#nephsky #kidney #CKD #Lipid #cholesterol

youtu.be/Qq5BXEbhF2k?...

@divyaveerssneph.bsky.socialSep 30, 2026, 3:05 PM

Grateful to my institute PGIMER, Chandigarh and all my collaborators for our publication in 'the CJASN' on anemia in CKD 🙏🙏🙏
A ton of thanks to Indian Council of Medical Research (ICMR) for funding this project in #kidney #disease @asnpublications.bsky.social #ASNCJASN
#Nephsky #Nephbluesky

@sodatroubles.bsky.socialSep 30, 2026, 11:08 AM

An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression
#nephsky #nephrology
www.kidney-international.org/article/S008...